Germany Rainer Westermann, chairman of the Life Sciences Acceleration Alliance e.V. looks out over the choppy waters for life sciences venture capitalists in Europe over 2025. Three key initiatives stand to reshape the continent’s investment climate, but broader geopolitical winds – especially those now emanating from the White House – could…
Saudi Arabia Dr. Helmut M. Schuehsler, CEO of TVM Capital Healthcare, shares insights into the firm’s investment strategy spanning the Middle East and Southeast Asia with a particular focus on Saudi Arabia’s rapidly evolving healthcare landscape. He discusses how TVM Capital Healthcare is driving transformation by scaling healthcare businesses, introducing innovative care…
Switzerland Dominik Escher, Managing Partner of Pureos Bioventures explores the firm’s strategic focus on drug development, particularly in biologics and antibody-based therapeutics. With a keen emphasis on the Swiss biotech ecosystem, Escher discusses the firm’s investment approach and its commitment to fostering innovation in Europe and beyond. Swiss biotech stands…
Hong Kong Chuen Yan Leung leads life science-focused venture capital firm Silver Dart Capital based out of Hong Kong and also serves as vice chairman of the Hong Kong Biotechnology Organization. In conversation, Leung outlines Silver Dart’s investments in growth-stage healthcare companies that are already scientifically de-risked and generating revenue; some of…
Hong Kong Sabrina Chan, senior executive director of the Hong Kong Association of the Pharmaceutical Industry (HKAPI), an organization that represents the innovative pharmaceutical industry in Hong Kong and Macau, weighs in on regulatory improvements in the territory such as the OnePlus mechanism and the Centre for Medical Products Regulation; discusses HKAPI’s…
Italy Some of the biggest pharma and healthcare stories coming out of Italy, including Italy’s antitrust investigation of Novartis and Genentech; Johnson & Johnson’s EUR 125 million investment in its Italian manufacturing site; Chiesi Farmaceutici’s licensing agreement with Gossamer Bio for a pulmonary hypertension drug, and Menarini and Insilico’s oncology partnership.…
Hong Kong VMS Group was founded in 2006 and since then has built close relationships with a handful of large anchor investors, including some of the largest families in Hong Kong. Apart from managing over USD 4.3 billion across its three in-house strategies – Private Equity, Real Estate and Structured Finance, it…
Italy A roundup of some of the biggest stories from Italian pharma and healthcare, including Italfarmaco’s FDA approval for its DMD treatment; Alfasigma’s acquisition of Galapagos’s Jyseleca, the antibiotics deal between Venatorx Pharmaceuticals and Menarini, and the country’s drop in healthcare spending. Stevanato Group Announces Public Offering of Ordinary Shares…
India India’s National Chemical Laboratory (NCL), one of the most well-established labs in the wider Council of Scientific and Industrial Research (CSIR) network, has made some major contributions to improving the country’s manufacturing processes for pharmaceutical intermediates and APIs. Director Dr Ashish Lele outlines the approaches the lab is pursuing, such…
India Shailesh Siroya explains the rationale behind Bal Pharma’s strategic focus on niche products within the API segment, avoiding the broader, more competitive commodity markets and enabling it to establish a significant global presence. Siroya also outlines how Bal Pharma has evolved from its initial focus on the export market to…
India The Indian pharma industry has demonstrated spectacular growth based on its strength as a global generics manufacturer. Yet Indian pharma is not merely resting on its laurels. After shining through the COVID-19 pandemic and despite recent quality issues, the country’s pharmaceutical sector is looking to refocus its efforts on innovation…
USA Francesco Lanucara of PharmaLex, writing in the November 2023 edition of the DIA’s Global Forum magazine takes a look at how new guidance from the US FDA aims to tackle the myriad challenges of cell and gene therapy manufacturing comparability and complexity. Development of cell and gene therapy (CGT)…
See our Cookie Privacy Policy Here
